Literature DB >> 8423074

Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.

C H Mody1, R M Syme.   

Abstract

Cryptococcus neoformans is a pathogenic encapsulated yeast that infects patients that have defective cell-mediated immunity, including AIDS patients. Whole cryptococcal organisms that are killed by heating stimulate normal human lymphocytes to proliferate. However, strains of C. neoformans vary widely in virulence and therefore in their ability to cause disease in humans. To determine the effect of virulence factors such as the cryptococcal capsule, serotype, and the state of the organisms on the lymphocyte response to C. neoformans, human peripheral blood mononuclear cells were stimulated with C. neoformans in vitro and lymphocyte proliferation was determined. The major determinant of the lymphocyte response to C. neoformans was the amount of polysaccharide present. The response was greater after stimulation by minimally encapsulated strains (strains C3D, 68, and 613) than by heavily encapsulated strains (strains 6 and 145). A heavily encapsulated strain (strain 6) did not suppress the response to an acapsular mutant (strain 67). However, the response to an acapsular strain was suppressed by the addition of purified polysaccharide. Human lymphocytes responded to both serotypes of C. neoformans var. neoformans. The antigen responsible for lymphocyte stimulation was preserved despite various techniques of inactivation, including heat, paraformaldehyde fixation, irradiation, and mechanical disruption. Finally, lymphocytes responded equally to live and killed organisms. These results suggest that capsular polysaccharide, a known virulence factor, may suppress the human lymphocyte response to C. neoformans during an infection. Lymphocytes could respond to C. neoformans regardless of the viability of the organism, and they could also respond to disrupted organisms. We speculate that lymphocyte proliferation in vitro could be related to the protective immune response in host defense to C. neoformans and that it is suppressed by virulence factors of C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423074      PMCID: PMC302751          DOI: 10.1128/iai.61.2.464-469.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Cell-mediated immunity in Cryptococcosis.

Authors:  J R Graybill; R H Alford
Journal:  Cell Immunol       Date:  1974-10       Impact factor: 4.868

2.  Poorly encapsulated Cryptococcus neoformans from patients with AIDS. I: Preliminary observations.

Authors:  E J Bottone; M Toma; B E Johansson; G P Wormser
Journal:  AIDS Res       Date:  1986

3.  Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans.

Authors:  E S Jacobson; D J Ayers; A C Harrell; C C Nicholas
Journal:  J Bacteriol       Date:  1982-06       Impact factor: 3.490

4.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

Authors:  T R Kozel; C A Hermerath
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

5.  Growth of Cryptococcus neoformans within human macrophages in vitro.

Authors:  R D Diamond; J E Bennett
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

6.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

7.  In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans.

Authors:  T G Mitchell; L Friedman
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441

8.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

9.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

10.  Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells.

Authors:  J O Hill; A G Harmsen
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  24 in total

1.  Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate.

Authors:  C H Mody; K L Sims; C J Wood; R M Syme; J C Spurrell; M M Sexton
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

2.  Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection.

Authors:  B C Fries; C P Taborda; E Serfass; A Casadevall
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans.

Authors:  D Pietrella; R Cherniak; C Strappini; S Perito; P Mosci; F Bistoni; A Vecchiarelli
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Both CD4+ and CD8+ human lymphocytes are activated and proliferate in response to Cryptococcus neoformans.

Authors:  R M Syme; C J Wood; H Wong; C H Mody
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

5.  Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes.

Authors:  Rachel M Syme; Jason C L Spurrell; Ernest K Amankwah; Francis H Y Green; Christopher H Mody
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 7.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

8.  In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.

Authors:  C H Mody; G H Chen; C Jackson; J L Curtis; G B Toews
Journal:  Mycopathologia       Date:  1994-01       Impact factor: 2.574

9.  Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response.

Authors:  Abraham Guerrero; Bettina C Fries
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

10.  Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella.

Authors:  Nuria Trevijano-Contador; Inés Herrero-Fernández; Irene García-Barbazán; Liliana Scorzoni; Cristina Rueda; Suélen Andreia Rossi; Rocío García-Rodas; Oscar Zaragoza
Journal:  Virulence       Date:  2015       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.